Kalaris Therapeutics, Inc. 8-K

What Happened

• On March 9, 2026, Kalaris Therapeutics, Inc. (KLRS) made available an updated corporate presentation (attached as Exhibit 99.1) under Regulation FD. The presentation, to be used at The Leerink Partners Global Healthcare Conference and other investor/analyst meetings, includes updated timelines for reporting data from the Company’s Phase 1b/2 multi-ascending dose trial of TH103 and plans to initiate Phase 3 clinical development. The presentation also provides clinical operations updates and cash runway guidance.
• The company furnished the presentation in a Form 8-K; the disclosure is being furnished (not “filed”) and includes forward‑looking statements subject to risks and uncertainties.

Key Details

• Date filed: March 9, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Presentation attached as Exhibit 99.1 and intended for investor/analyst conferences, including The Leerink Partners Global Healthcare Conference.
• Material updates cover timelines for Phase 1b/2 TH103 data reporting and initiation of Phase 3, plus clinical operations and cash runway guidance.
• Disclosure is furnished under Regulation FD and contains forward‑looking statements with standard risk disclosures.

Why It Matters

• For investors, the update signals the company’s current expectations on TH103 clinical milestones and provides cash runway context—both key to assessing development progress and financing needs. Because the information is furnished under Regulation FD, it represents a public, company-approved update on near-term clinical and operational plans, though timelines remain subject to change per the forward‑looking statements.